SCHEMBL17737360

SCHEMBL17737360

COc1cccc(S(=O)(=O)Nc2cccc3cnccc23)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 3/20 0.64
▸ GLO1 Q04760 2/20 0.64
▸ KEAP1 Q14145 2/20 0.63
▸ NFE2L2 Q16236 2/20 0.63
▸ GAA P10253 1/20 0.61
▸ IDO1 P14902 1/20 0.59
▸ CNR2 P34972 1/20 0.56
▸ CYP11B1 P15538 1/20 0.56
▸ CYP11B2 P19099 1/20 0.56
▸ ALPL P05186 1/20 0.54
▸ DDX3X O00571 1/20 0.52
▸ LMNA P02545 2/20 0.50
▸ FFAR4 Q5NUL3 1/20 0.50
▸ PTGES2 Q9H7Z7 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ PGR P06401 2/20 0.48
▸ TRPV1 Q8NER1 1/20 0.47
▸ SLC22A12 Q96S37 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17737442 0.88 GLO1 (0.62) SLC40A1GLO1KEAP1NFE2L2GAA
SCHEMBL17737451 0.85 IDO1 (0.56) SLC40A1GLO1KEAP1NFE2L2GAA
SCHEMBL17737448 0.85 KEAP1 (0.62) KEAP1NFE2L2IDO1CNR2DDX3X
SCHEMBL17737675 0.84 IDO1 (0.63) SLC40A1GLO1GAAIDO1CNR2
SCHEMBL17737767 0.83 IDO1 (0.67) GLO1IDO1CNR2DDX3XLMNA
SCHEMBL19852956 0.82 RECQL (0.69) SLC40A1GLO1IDO1DDX3XALDH1A1
SCHEMBL17737365 0.81 IDO1 (0.63) SLC40A1GLO1IDO1CNR2DDX3X
SCHEMBL19852954 0.79 IDO1 (0.62) SLC40A1KEAP1NFE2L2IDO1DDX3X
SCHEMBL17737441 0.79 IDO1 (0.62) SLC40A1GLO1KEAP1IDO1CNR2
SCHEMBL11973668 0.78 SLC40A1 (1.00) SLC40A1GLO1LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215155-B1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2020-10-14 — — EP disclosed
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase IOMET PHARMA LTD. (GB) 2019-05-14 — — US disclosed
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2018-02-08 — — US disclosed
WO-2016071283-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2016-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase TDO2, IDO2, IDO1 SLC40A1 2382/4885GLO1 936/4885KEAP1 1682/4885
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE TDO2, IDO2, IDO1 SLC40A1 2382/4885GLO1 936/4885KEAP1 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback